Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus.

Lai ZW, Borsuk R, Shadakshari A, Yu J, Dawood M, Garcia R, Francis L, Tily H, Bartos A, Faraone SV, Phillips P, Perl A.

J Immunol. 2013 Sep 1;191(5):2236-46. doi: 10.4049/jimmunol.1301005. Epub 2013 Aug 2.

2.

N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.

Lai ZW, Hanczko R, Bonilla E, Caza TN, Clair B, Bartos A, Miklossy G, Jimah J, Doherty E, Tily H, Francis L, Garcia R, Dawood M, Yu J, Ramos I, Coman I, Faraone SV, Phillips PE, Perl A.

Arthritis Rheum. 2012 Sep;64(9):2937-46. doi: 10.1002/art.34502.

3.

Detection of lupus anticoagulant and successful anticoagulation in familial Sneddon syndrome.

Tily H, Banki K, Hoffman GS, Perl A.

Ann Rheum Dis. 2010 Apr;69(4):775-6. doi: 10.1136/ard.2009.108746. No abstract available.

PMID:
20237126
4.

Lymphoedema: a paradoxical effect of tumour necrosis factor inhibitors - case report and review of literature.

Tily HI, Perl A.

BMJ Case Rep. 2009;2009. pii: bcr07.2008.0520. doi: 10.1136/bcr.07.2008.0520. Epub 2009 Mar 5.

5.

Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus.

Rhew EY, Lee C, Eksarko P, Dyer AR, Tily H, Spies S, Pope RM, Ramsey-Goldman R.

J Rheumatol. 2008 Feb;35(2):230-6. Epub 2008 Jan 15.

PMID:
18203323
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk